SERMONIX PHARMACEUTICALS
Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company, focuses on the development and commercialization of late-stage women’s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company was founded in 2014 and is headquartered in Columbus, Ohio.
SERMONIX PHARMACEUTICALS
Industry:
Biopharma Clinical Trials Pharmaceutical
Founded:
2014-01-01
Address:
Columbus, Ohio, United States
Country:
United States
Website Url:
http://www.sermonixpharma.com
Total Employee:
1+
Status:
Active
Contact:
(614)864-4919
Email Addresses:
[email protected]
Total Funding:
67.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag Mobile Non Scaleable Content
Current Advisors List
Current Employees Featured
Founder
Investors List
Perceptive Advisors
Perceptive Advisors investment in Series A - Sermonix Pharmaceuticals
Anthony Wild
Anthony Wild investment in Series A - Sermonix Pharmaceuticals
WILD Family Office
WILD Family Office investment in Series A - Sermonix Pharmaceuticals
Lodewijk de Vink
Lodewijk de Vink investment in Series A - Sermonix Pharmaceuticals
Richard DeSchutter
Richard DeSchutter investment in Series A - Sermonix Pharmaceuticals
Official Site Inspections
http://www.sermonixpharma.com Semrush global rank: 7.23 M Semrush visits lastest month: 551
- Host name: ec2-3-145-15-89.us-east-2.compute.amazonaws.com
- IP address: 3.145.15.89
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Sermonix Pharmaceuticals"
Sermonix Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (614)864-4919 Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company, focuses on the development and …See details»
Company Overview | Sermonix Pharmaceuticals
New activity in ESR1. mutations was discovered in the laboratory of Donald McDonnell, MD, at Duke University, and Sermonix has exclusive rights to develop and, if FDA-approved, commercialize lasofoxifene in this important area of …See details»
Sermonix Pharmaceuticals
The ELAINE Study is an open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and …See details»
Sermonix Pharmaceuticals Company Profile | Management and
Www.sermonixpharma.com Sermonix Pharmaceuticals Profile and History Founded in 2014 and headquartered in Colombus, United States, Sermonix Pharmaceuticals is a biopharmaceutical …See details»
Sermonix Pharmaceuticals Company Overview, Contact Details ...
Nov 15, 2021 Jun 08, 2022 | sermonixpharma.com. Sermonix Pharmaceuticals Inc. received financing of $40M in Series A3 on Nov 15th '21. Sermonix, a Columbus OH-based …See details»
Sermonix Pharmaceuticals - Overview, News & Similar ... - ZoomInfo
Jun 4, 2023 Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024 COLUMBUS, Ohio, April 19, 2024 (GLOBE …See details»
Sermonix Pharmaceuticals - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Sermonix Pharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Sermonix Pharmaceuticals LLC - Drug pipelines, Patents ... - Patsnap
Learn more at SermonixPharma.com. Sermonix Contact: Elizabeth Attias, Sc.D. Chief Strategy and Development Officer [email protected] (973) 723-7832. ... The statistics for …See details»
Sermonix Pharmaceuticals - LinkedIn
Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1 …See details»
Management Team | Sermonix Pharmaceuticals
Simon Jenkins, PhD, VP of Operations Simon Jenkins, PhD, joined Sermonix Pharmaceuticals as vice president of Operations in 2018. Simon has over 30 years of experience in global drug development leadership roles across a …See details»
Sermonix Pharmaceuticals - Funding, Financials, Valuation
Sermonix Pharmaceuticals is an Ohio LLC specialty pharmaceutical. Sermonix Pharmaceuticals has a post-money valuation in the range of $100M to $500M as of Nov 29, 2021, according to …See details»
Sermonix Pharmaceuticals, LLC | Ohio Life Sciences
Sermonix Pharmaceuticals is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products.See details»
Sermonix Pharmaceuticals - Craft
Sermonix Pharmaceuticals has 1 employees at their 1 location and $27.6 m in total funding,. See insights on Sermonix Pharmaceuticals including office locations, competitors, revenue, …See details»
Sermonix Pharmaceuticals LLC (Sermonix Pharmaceuticals LLC)
To learn more about Sermonix, visit SermonixPharma.com. To learn more about the ELAINE studies, visit DiscoverElaine.com. About Henlius Henlius (2696.HK) is a global …See details»
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing …
Nov 15, 2021 Sermonix recently announced significant progress in the advancement of its ELAINE (Evaluation of Lasofoxifene in ESR1 Mutations) Phase 2 clinical program for …See details»
Sermonix Pharmaceuticals Closes US$26 Million ... - Treehill Partners
Jul 31, 2019 Proceeds will be used to fund Phase 2 ELAINE clinical trial, which is currently enrolling, to develop lasofoxifene as a potential precision medicine for metastatic breast …See details»
Sermonix Pharmaceuticals Announces JCO Precision Oncology …
Nov 8, 2023 Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical …See details»
Sermonix Pharmaceuticals Completes Enrollment of Phase 2
Aug 27, 2024 Quantum Leap Healthcare Collaborative is a 501c(3) charitable organization established in 2005 as a collaboration between medical researchers at University of California, …See details»
Sermonix and Henlius Dose First Chinese Patient in Phase 3
5 hours ago [email protected] (973) 723-7832. Tags Sermonix Pharmaceuticals Shanghai Henlius Biotech Inc. lasofoxifene ELAINE-3 China ER+/HER2-metastatic breast …See details»
sermonix | Sermonix Pharmaceuticals
Dec 16, 2019 Recent Posts. Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 …See details»